Skip to main content

Breast Cancer

Featured Article
In a Managed Care Learning Network session, Adam M Brufsky, MD, PhD, and Edward Li, PharmD, MPH, outlined the clinical and cost implications of HER2+ breast cancer treatment in the era of biosimilars…
Adam Brufsky, MD, PhD, and Sreejata Raychaudhuri, MD, recently discussed how the novel HER2+ therapies fit into breast cancer treatment.
Back to Top